Abstract CT256: EmpowHER-303: A phase 3 study of zanidatamab vs trastuzumab with physician’s choice of chemotherapy in patients with HER2+ metastatic breast cancer whose disease progressed on trastuzumab deruxtecan
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Sara M. Tolaney, Javier Cortes, Erika Hamilton, Hiroji Iwata, Yeon Hee Park, Debasish Tripathy, Romualdo Barroso-Sousa, Giuseppe Curigliano, Nadia Harbeck, Hope S. Rugo, Shanu Modi, Joshua Drago, Stephanie L. Graff, Carlos Barrios, Hartmut Kristeleit, Barbara Pistilli, Philippe Aftimos, Shigehira Saji, Angelos Koutras, Debasis Chakrabarti, Kamalnayan Bhatt, George Cai, Xiaoyan Wang, Sara Hurvitz
Institutions: Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology, Sarah Cannon, Nagoya City University, Samsung Medical Center, The University of Texas MD Anderson Cancer Center, European Institute of Oncology, LMU Klinikum, Ludwig-Maximilians-Universität München, UCSF Helen Diller Family Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Brown University, Lifespan, Latin American Cooperative Oncology Group (LACOG), Guy's and St Thomas' NHS Foundation Trust, Institut Gustave Roussy, Institut Jules Bordet, Fukushima Medical University, University of Patras, Jazz Pharmaceuticals (United States), University of Washington, Fred Hutch Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821665